U.S. still faces possible default wave, asset declines due to pandemic: Fed
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/13/2026
- S&P 500, Nasdaq futures decline as US-Iran escalation rattles sentiment
- Oil gains over 2% as fresh military strikes threaten Hormuz shipments
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Apple sues OpenAI, two former employees for trade secrets theft
Pfizer (PFE) Reports Positive Results from Fifth Phase 3 Trial of Abrocitinib
November 11, 2020 6:46 AM ESTPfizer Inc. (NYSE: PFE) announced today positive top-line results from the Phase 3 JADE REGIMEN study. This 52-week study investigated abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, in patients 12 and older with moderate to severe atopic dermatitis (AD) following response to initial open label induction treatment with abrocitinib 200mg. Patients were randomized... More
